
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health is positioned as a dominant liquid-biopsy leader with durable franchises in Guardant360, Reveal, and Shield, supported by strong clinical validation, broad NCCN and ACS guideline inclusion, and a large prospective ECLIPSE study. Its outlook is reinforced by accelerating Q1’26 momentum, including $302M revenue, +48% Y/Y growth, 86k oncology tests, a 65% GAAP gross margin, $1.2B of cash, and a raised 2026 revenue guide of $1.30-1.32B. The company also has multiple monetization catalysts ahead, including broader Shield coverage, higher ASPs from reimbursement and ADLT status, and expanding sales reach, which together support sustained double-digit growth and improving profitability.
Bears say
Guardant Health is facing a fundamentally fragile growth story because its upside is concentrated in Shield while its broader franchise remains exposed to slower adoption, reimbursement uncertainty, and a smaller-than-expected market for blood-based screening. Although Q1'26 Shield CRC revenue of about $42M and ~44k volumes beat expectations, the company still depends on Medicare pricing of $1,495/test through YE'27, and margins may compress as it expands beyond that population. Meanwhile, Reveal’s upcoming MRD push enters a crowded market, and the company has burned more than $200M in cash in each of the past two years, with accelerating burn and execution risk around its Q4 2027 breakeven goal.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares